Home › Funds › Ally Bridge Group (NY) LLC › URGN
Ally Bridge Group (NY) LLC position in URGN
UROGEN PHARMA LTD COM · Health Care
Ally Bridge Group (NY) LLC reported holding 69,183 shares of URGN (UROGEN PHARMA LTD COM) in its Q2 2026 13F filing — a position valued at US$2.5M, representing 2.25% of its reported portfolio and ranking #17 among its reported holdings. Ally Bridge Group (NY) LLC has disclosed URGN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ally Bridge Group (NY) LLC's URGN position evolved
Ally Bridge Group (NY) LLC first disclosed a stake in URGN in Q1 2026 at 202,124 shares (US$3.6M). Across 2 filings, Ally Bridge Group (NY) LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 69,183 shares valued at US$2.5M — a reduction of -132,941 shares quarter over quarter.. Notable position changes include a 66% trim in Q2 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 202.12K | $3.63M | New |
| Q2 2026 | 69.18K | $2.55M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD COM) is a Health Care company. 40 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M sh · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M sh · $80.95M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M sh · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M sh · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.30M sh · $47.91M · Q2 2026
- MPM BioImpact LLC 933.41K sh · $34.35M · Q2 2026
- Soleus Capital Management, L.P. 829.81K sh · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K sh · $18.40M · Q2 2026
- Privium Fund Management B.V. 210.00K sh · $7.73M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K sh · $7.04M · Q2 2026
More on Ally Bridge Group (NY) LLC
FAQ
How long has Ally Bridge Group (NY) LLC held URGN?
Ally Bridge Group (NY) LLC has disclosed URGN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Ally Bridge Group (NY) LLC's current position in URGN?
As of Q2 2026, Ally Bridge Group (NY) LLC holds 69.18K shares of URGN (UROGEN PHARMA LTD COM), valued at $2.55M, representing 2.25% of its reported portfolio and ranking #17.
Has Ally Bridge Group (NY) LLC been buying or selling URGN?
In the latest 13F filing (Q2 2026), Ally Bridge Group (NY) LLC reduced its position in URGN.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.